Lisocabtagene Maraleucel,ibrutinib,venetoclax
Bms,Roche,Abbvie
['cll']
discussant somewhat confidently suggested that car t was already better than allosct in cll while clearly less toxic, i think it is too early to say whether car t is sufficiently efficacious / durable to replace allosct in young pts/multiply-relapsed/high-risk dz
#asco23 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem